{"id":45748,"date":"2022-07-01T15:02:01","date_gmt":"2022-07-01T13:02:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/"},"modified":"2022-07-01T15:02:01","modified_gmt":"2022-07-01T13:02:01","slug":"iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/","title":{"rendered":"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies"},"content":{"rendered":"<div>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter\u2122 single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy. These data will be presented during the 2022 European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, taking place in Prague, Czech Republic on July 1-3, 2022.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220701005014\/en\/1500981\/5\/MicrosoftTeams-image_%281%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220701005014\/en\/1500981\/21\/MicrosoftTeams-image_%281%29.jpg\"><\/a><\/p>\n<p>\n<b>Highlights from the EAACI Data<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThrough an unbiased discovery approach IgGenix has discovered and re-engineered IgE antibodies as IgG antibodies to block the reactive molecules underlying allergic disease.\n<\/li>\n<li>\nMonoclonal antibodies (mAbs) discovered from tree nut allergic individuals exhibited a range of affinities, with many demonstrating high affinity in the sub-nanomolar range.\n<\/li>\n<li>\nSelect mAbs studied exhibited cross-reactivity to multiple tree nut allergens, including the pairs of cashew and pistachio, as well as pecan and walnut \u2013 highlighting potential future use of this therapeutic model to address tree nut co-allergies.\n<\/li>\n<li>\nA more targeted therapeutic approach for patients has the potential to address key allergens directly with better safety than allergen-oriented approaches and a quicker onset of action.\n<\/li>\n<\/ul>\n<p>\n\u201c<!-- no quote -->These insights provide a molecular basis for clinical co-allergy to multiple tree nuts and provide an encouraging beginning for developing therapeutics to target the key allergens driving tree nut allergy,\u201d said Derek Croote, Co-Founder and Chief Technical Officer of IgGenix. \u201c<!-- no quote -->At IgGenix, we are developing a novel approach to treating allergic disease. These data are the potential basis for treatments that may block and prevent life-threatening allergic reactions.\u201d\n<\/p>\n<p>\n<b>Title: <\/b>Cross-reactive, High-affinity Monoclonal IgE Antibodies Underlie Tree Nut Co-Allergy (#100220)<br \/>\n<br \/><b>Authors: <\/b>Croote D., Creeks P., Romero J., Sohail S., Lowman H.B., Wong J. J.W.<br \/>\n<br \/><b>Presenter: <\/b>Derek Croote, Ph.D.\n<\/p>\n<p>\nThe abstract can be accessed <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Figgenix.com%2Fpublications%2F&amp;esheet=52766150&amp;newsitemid=20220701005014&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=e9e6f398964d29cf77bf6845bb9b595c\" rel=\"nofollow noopener\" shape=\"rect\">here<\/a>.\n<\/p>\n<p>\n<b>About IgGenix<\/b>\n<\/p>\n<p>\nIgGenix is a privately held biotechnology company taking a revolutionary approach to directly alleviate food and other severe allergies by reengineering key antibodies involved in the allergic cascade. Founded based on research by Stephen Quake, Kari Nadeau, and Derek Croote of a novel discovery platform developed at Stanford University, IgGenix isolates rare allergen-specific IgE antibodies responsible for allergic reactions and transforms them into IgG antibodies. These therapeutic IgG antibodies are designed to alleviate and possibly prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects people living with severe allergies.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nFor Investor Inquiries:<br \/>\n<br \/>Jessica Grossman<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#111;&#x3a;&#106;&#x67;r&#x6f;s&#115;&#x6d;&#97;&#x6e;&#64;&#x69;&#x67;&#103;&#x65;n&#x69;x&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#106;&#x67;&#114;&#x6f;&#115;&#x73;&#109;&#x61;&#110;&#x40;&#105;&#x67;&#103;&#x65;&#110;&#x69;&#120;&#x2e;&#99;&#x6f;&#109;<\/a><\/p>\n<p>For Media Inquiries:<br \/>\n<br \/>Tyler Glynn<br \/>\n<br \/>843-575-0355<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;&#58;&#x74;&#x67;&#108;&#x79;&#x6e;&#110;&#x40;&#x6a;&#112;&#x61;&#x2e;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x74;&#103;&#108;&#x79;&#x6e;&#110;&#64;&#x6a;&#x70;&#97;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter\u2122 single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy. These data will be presented during the 2022 European Academy of Allergy and Clinical Immunology &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45748","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter\u2122 single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy. These data will be presented during the 2022 European Academy of Allergy and Clinical Immunology ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-01T13:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220701005014\/en\/1500981\/21\/MicrosoftTeams-image_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies\",\"datePublished\":\"2022-07-01T13:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/\"},\"wordCount\":412,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005014\\\/en\\\/1500981\\\/21\\\/MicrosoftTeams-image_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/\",\"name\":\"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005014\\\/en\\\/1500981\\\/21\\\/MicrosoftTeams-image_%281%29.jpg\",\"datePublished\":\"2022-07-01T13:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005014\\\/en\\\/1500981\\\/21\\\/MicrosoftTeams-image_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005014\\\/en\\\/1500981\\\/21\\\/MicrosoftTeams-image_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/","og_locale":"en_US","og_type":"article","og_title":"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter\u2122 single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy. These data will be presented during the 2022 European Academy of Allergy and Clinical Immunology ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-01T13:02:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220701005014\/en\/1500981\/21\/MicrosoftTeams-image_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies","datePublished":"2022-07-01T13:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/"},"wordCount":412,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220701005014\/en\/1500981\/21\/MicrosoftTeams-image_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/","url":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/","name":"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220701005014\/en\/1500981\/21\/MicrosoftTeams-image_%281%29.jpg","datePublished":"2022-07-01T13:02:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220701005014\/en\/1500981\/21\/MicrosoftTeams-image_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220701005014\/en\/1500981\/21\/MicrosoftTeams-image_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/iggenix-demonstrates-potential-for-single-cell-rna-sequencing-in-tree-nut-allergies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45748"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45748\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}